Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

Palbociclib and Pembrolizumab In Central Nervous System MetastasesRecruiting
NCT02896335Phase 2Updated Jul 21, 2026
Sponsor: Massachusetts General Hospital
Metastatic Malignant Neoplasm to Brain · Recurrent Brain Metastases · Progressive Brain Metastases
United States
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other CancersRecruiting
NCT05098132Phase 1, Phase 2Updated Jul 21, 2026
Sponsor: Synthekine
Advanced Solid Tumor · Non Small Cell Lung Cancer · Untreated Advanced NSCLC · 1st Line NSCLC
United States, Georgia, Ireland, Spain
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)Completed
NCT04949256Phase 3Updated Jul 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Metastatic Esophageal Squamous Cell Carcinoma
United States, Argentina, Canada, Chile, China +20 more
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)Recruiting
NCT04924075Phase 2Updated Jul 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Pheochromocytoma/Paraganglioma · Pancreatic Neuroendocrine Tumor · Von Hippel-Lindau Disease · Advanced Gastrointestinal Stromal Tumor
United States, Australia, Canada, Chile, China +17 more
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)Recruiting
NCT06442436Phase 1Updated Jul 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Hepatic Impairment (HI)
United States
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)Recruiting
NCT06136559Phase 3Updated Jul 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
United States, Australia, Belgium, Brazil, Canada +24 more
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)Recruiting
NCT07190248Phase 3Updated Jul 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +24 more
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruiting
NCT07327229Phase 1, Phase 2Updated Jul 20, 2026
Sponsor: Antengene Biologics Limited
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
China
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Recruiting
NCT07227597Phase 1, Phase 2Updated Jul 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Small Cell Lung Cancer Extensive Stage
United States, Argentina, Chile, China, Germany +4 more
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)Recruiting
NCT07133633Phase 2Updated Jul 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Radiographic Axial Spondyloarthritis
United States, Brazil, Canada, Chile, China +9 more
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)Recruiting
NCT07071623Phase 3Updated Jul 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Human Immunodeficiency Virus (HIV) · HIV Pre-Exposure Prophylaxis
Kenya, South Africa, Uganda
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]Recruiting
NCT06422143Phase 3Updated Jul 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer · NSCLC
United States, Argentina, Austria, Brazil, Canada +21 more
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)Active Not Recruiting
NCT05540327Phase 2Updated Jul 20, 2026
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
United States, Argentina, Australia, Brazil, Bulgaria +17 more
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)Recruiting
NCT07044297Phase 3Updated Jul 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Human Immunodeficiency Virus (HIV) · HIV Pre-Exposure Prophylaxis
United States, Argentina, Brazil, Chile, Colombia +11 more
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)Recruiting
NCT06312137Phase 3Updated Jul 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +26 more
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)Recruiting
NCT06170788Phase 3Updated Jul 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
United States, Argentina, Australia, Brazil, Canada +21 more
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)Recruiting
NCT07614984Phase 2Updated Jul 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Lipoprotein(a)
United States
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)Active Not Recruiting
NCT06305754Phase 3Updated Jul 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
United States, Argentina, Canada, China, Colombia +14 more
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)Recruiting
NCT07363590Phase 1Updated Jul 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Systemic Lupus Erythematosus · Rheumatoid Arthritis
Australia, Belgium, China, Colombia, Georgia +5 more
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)Recruiting
NCT07554339Phase 3Updated Jul 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
United States, Argentina, Greece, Netherlands, South Korea +3 more
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaActive Not Recruiting
NCT03069378Phase 2Updated Jul 17, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Sarcoma · Epithelioid Sarcoma · Cutaneous Angiosarcoma
United States
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Active Not Recruiting
NCT06079879Phase 3Updated Jul 17, 2026
Sponsor: Merck Sharp & Dohme LLC
Essential Thrombocythemia
United States, Argentina, Australia, Belgium, Canada +19 more
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)Recruiting
NCT06380738N/AUpdated Jul 17, 2026
Sponsor: AstraZeneca
Metastatic Castration-resistant Prostate Cancer
Germany
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)Recruiting
NCT07463183Phase 2Updated Jul 17, 2026
Sponsor: Merck Sharp & Dohme LLC
Colitis Ulcerative · Ulcerative Colitis
United States, Netherlands, South Korea
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)Recruiting
NCT07222488Phase 1, Phase 2Updated Jul 17, 2026
Sponsor: Merck Sharp & Dohme LLC
Bladder Cancer · Urinary Bladder Neoplasms
United States, Austria, Belgium, Canada, France +7 more

Previous page Next page